Comparative Pharmacology
Head-to-head clinical analysis: LODINE versus LODINE XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODINE versus LODINE XL.
LODINE vs LODINE XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis leading to anti-inflammatory, analgesic, and antipyretic effects.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
400 mg or 600 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
Terminal elimination half-life is approximately 6-7 hours. Steady-state is achieved within 2 days.
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Renal excretion of metabolites accounts for approximately 70% of a dose; fecal excretion accounts for about 20%.
Category C
Category C
NSAID
NSAID